Report from the fifth national cancer institute mouse models of human cancers consortium nervous system tumors workshop

Neuro-Oncology

Volumn 13, Issue 7, 2011, Pages 692-699

  Gutmann, David H ^a   Stiles, Charles D ^b   Lowe, Scott W ^c   Bollag, Gideon E ^d   Furnari, Frank B ^e   Charest, Al ^f  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c Simons Center for Quantitative Biology   (United States)

^d PLEXXIKON INC   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Brain tumor; Genetically engineered mice; Glioma; Medulloblastoma; Xenograft

Indexed keywords

ASTROCYTOMA; CANCER CENTER; CANCER GENETICS; CANCER GROWTH; CANCER MODEL; CARCINOGENESIS; CONFERENCE PAPER; GENE MUTATION; GENE SEQUENCE; GENETIC ENGINEERING; GLIOBLASTOMA; HISTOPATHOLOGY; NERVOUS SYSTEM TUMOR; NEURILEMOMA; NONHUMAN; PILOCYTIC ASTROCYTOMA; PROGNOSIS;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; MICE; NATIONAL CANCER INSTITUTE (U.S.); NERVOUS SYSTEM NEOPLASMS; UNITED STATES;

EID: 80052778096     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nor080     Document Type: Conference Paper

References (28)

1. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114:97-109. (Pubitemid 47103521)
2. Sharma MK, Mansur DB, Reifenberger G, et al. Distinct genetic signatures among pilocytic astrocytomas relate to their brain region origin. Cancer Res. 2007;67:890-900.
3. Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17:98-110.
4. McLendon R, Friedman A, Bigner D, et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455:1061-1068.
5. Brennan C, Momota H, Hambardzumyan D, et al. Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations. PLoS One. 2009;4:e7752.
6. Gilbertson RJ, Gajjar A. Molecular biology of medulloblastoma: will it ever make a difference to clinical management? J Neurooncol. 2005;75:273-278. (Pubitemid 43019482)
7. Cho YJ, Tsherniak A, Tamayo P, et al. Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol. 2011;29:1424-1430.
8. Johnson RA, Wright KD, Poppleton H, et al. Cross-species genomics matches driver mutations and cell compartments to model ependymoma. Nature. 2010;466:632-636.
9. Lee J, Kotliarova S, Kotliarov Y, et al. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell. 2006;9:391-403. (Pubitemid 43668737)
10. Voskoglou-Nomikos T, Pater JL, Seymour L. Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin Cancer Res. 2003;9:4227-4239. (Pubitemid 37204044)
11. Ding H, Roncari L, Shannon P, et al. Astrocyte-specific expression of activated p21-ras results in malignant astrocytoma formation in a transgenic mouse model of human gliomas. Cancer Res. 2001;61:3826-3836. (Pubitemid 32695000)
12. Weiss WA, Burns MJ, Hackett C, et al. Genetic determinants of malignancy in a mouse model for oligodendroglioma. Cancer Res. 2003;63:1589-1595. (Pubitemid 36373648)
13. Bierie B, Moses HL. Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer. 2006;6:506-520. (Pubitemid 43980540)
14. Weigelt B, Bissell MJ. Unraveling the microenvironmental influences on the normal mammary gland and breast cancer. Semin Cancer Biol. 2008;18:311-321.
15. Tlsty TD, Coussens LM. Tumor stroma and regulation of cancer development. Annu Rev Pathol. 2006;1:119-150.
16. Zhu Y, Ghosh P, Charnay P, et al. Neurofibromas in NF1:Schwann cell origin and role of tumor environment. Science. 2002;296:920-922. (Pubitemid 34464899)
17. Bajenaru ML, Hernandez MR, Perry A, et al. Optic nerve glioma in mice requires astrocyte Nf1 gene inactivation and Nf1 brain heterozygosity. Cancer Res. 2003;63:8573-8577. (Pubitemid 38064027)
18. Zhu Y, Harada T, Liu L, et al. Inactivation of NF1 in CNS causes increased glial progenitor proliferation and optic glioma formation. Development. 2005;132:5577-5588. (Pubitemid 43125883)
19. Yang FC, Ingram DA, Chen S, et al. Nf1-dependent tumors require a microenvironment containing Nf1+/- and c-kit-dependent bone marrow. Cell. 2008;135:437-448.
20. Daginakatte GC, Gutmann DH. Neurofibromatosis-1 (Nf1) heterozygous brain microglia elaborate paracrine factors that promote Nf1-deficient astrocyte and glioma growth. Hum Mol Genet. 2007;16:1098-1112. (Pubitemid 47062730)
21. Warrington NM, Woerner BM, Daginakatte GC, et al. Spatiotemporal differences in CXCL12 expression and cyclic AMP underlie the unique pattern of optic glioma growth in neurofibromatosis type 1. Cancer Res. 2007;67:8588-8595. (Pubitemid 47437434)
22. Relling MV, Dervieux T. Pharmacogenetics and cancer therapy. Nat Rev Cancer. 2001;1:99-108. (Pubitemid 33741885)
23. Hunter K. Host genetics influence tumour metastasis. Nat Rev Cancer. 2006;6:141-146. (Pubitemid 43361546)
24. Ryan BM, Robles AI, Harris CC. Genetic variation in microRNA networks: the implications for cancer research. Nat Rev Cancer. 2010;10:389-402.
25. Bosch TM. Pharmacogenomics of drug-metabolizing enzymes and drug transporters in chemotherapy. Methods Mol Biol. 2008;448:63-76.
26. Kim S, Hagemann A, DeMichele A. Immuno-modulatory gene polymorphisms and outcome in breast and ovarian cancer. Immunol Invest. 2009;38:324-340.
27. Whibley C, Pharoah PD, Hollstein M. p53 polymorphisms: cancer implications. Nat Rev Cancer. 2009;9:95-107.
28. Lee da Y, Yeh TH, Emnett RJ, et al. Neurofibromatosis-1 regulates neuroglial progenitor proliferation and glial differentiation in a brain regionspecific manner. Genes Dev. 2010;24:2317-2329.